Skip to main navigation
Pharvaris N.V. Logo
  • Careers
  • Investors & Media
  • Contact
  • SCIENCE
  • PIPELINE
  • DISEASE FOCUS
  • HAE COMMUNITY
  • CLINICAL TRIALS
  • ABOUT US

Event Details

Investor Menu

IR Nav

  • Overview
  • News & Events
    News Releases Events Publications
  • Financials
    SEC Filings Quarterly Results
  • Stock
    Stock Performance Analyst Coverage
  • Corporate Governance
    Governance Documents Leadership Board of Directors Committee Composition
  • Resources
    Investor FAQs Contact Us Email Alerts

AAAAI Annual Meeting 2023

Feb 26, 2023 9:45 AM CST

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 1.1 MB
Dr. Marcus Maurer Audio Session (MP4) 6.3 MB
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
Pharvaris N.V. Logo

CONTACT US

FOLLOW US

linkedin logo

©2023 Pharvaris N.V. © All Rights Reserved

  • Privacy Policy
  • Terms of Use